ESR1 and breast neoplasm: ERα is expressed in approximately 70% of all breast tumors and is the basis for the use of selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs), which substantially reduce the risk for disease recurrence and prolong patient survival.